New Treatment Cures 100% of Babesiosis Patients in Trial

For patients battling babesiosis with weakened immune systems, a new treatment combination has delivered something remarkable: every single person enrolled in a recent trial was cured.

60 Degrees Pharmaceuticals announced that all three patients in their expanded access study were cured of relapsing babesiosis after receiving a treatment regimen centered on tafenoquine, a malaria prevention drug. Combined with earlier Yale research showing similar results, seven out of seven immunosuppressed patients treated with this approach have been cured.

This matters because babesiosis is no minor illness. The tick-borne disease causes debilitating fevers, chills, sweats, and fatigue that can relapse multiple times in vulnerable patients. For elderly and immunosuppressed people, it can be life-threatening, and cases are rising across the United States.

The treatment combines tafenoquine with atovaquone and antibiotics, administered weekly until tests confirm the parasite is completely gone. What makes this approach special is its persistence: treatment continues for up to a year until two consecutive negative tests prove the infection has been eliminated.

Researchers then follow up 60 to 90 days later with an ultra-sensitive FDA-approved test that's 1,000 times more accurate than standard tests. Every patient passed this rigorous verification, confirming they were truly cured, not just in temporary remission.

One patient's journey particularly highlights the breakthrough. After failing an initial triple-drug combination in the Yale study, she received a four-drug regimen in the company trial that finally eliminated her infection for good.

The Ripple Effect

This success could transform care for thousands of people. Babesiosis often appears alongside Lyme disease, creating a double burden for patients bitten by infected ticks. Right now, no FDA-approved treatment exists specifically for babesiosis, leaving doctors to piece together solutions from existing medications.

The company is calling for medical guidelines to be updated based on these findings. While tafenoquine isn't yet approved for babesiosis treatment, it's already safely used for malaria prevention under the brand name ARAKODA, giving doctors a familiar starting point.

The rising incidence of tick-borne diseases makes this breakthrough timely. As tick populations expand into new regions, more people face exposure to babesiosis and its potentially devastating effects on health and quality of life.

For patients who've endured repeated relapses and failed treatments, this research offers something they desperately need: hope that a cure is within reach.